Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/53838
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChatlert Pongchaiyakulen_US
dc.contributor.authorRatanavadee Nanagaraen_US
dc.contributor.authorThawee Songpatanasilpen_US
dc.contributor.authorAasis Unnanuntanaen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPhramongkutklao Hospitalen_US
dc.date.accessioned2020-03-26T05:04:36Z-
dc.date.available2020-03-26T05:04:36Z-
dc.date.issued2020-01-01en_US
dc.identifier.citationJournal of Medical Economics. (2020)en_US
dc.identifier.issn1941837Xen_US
dc.identifier.issn13696998en_US
dc.identifier.other2-s2.0-85080933599en_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/53838-
dc.description.abstract© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Aims: This study assessed the cost-effectiveness of denosumab for treating postmenopausal women with osteoporosis (PMO) at high risk of fracture in Thailand. Materials and methods: A published Markov cohort cost-effectiveness model was populated with country-specific data as available and other published data as needed. The model used a societal perspective, lifetime horizon, efficacy data from network meta-analysis of trials, and included costs for direct medical and non-medical care, informal care, and osteoporosis treatments to compare denosumab to no pharmacologic treatment (calcium and vitamin D supplements only) and to oral weekly alendronate. The base case (high-risk population) included postmenopausal women with femoral neck T-score ≤−2.5, mean age 65 years at entry, and history of vertebral fracture. Results: High-risk women with osteoporosis using denosumab had the greatest number of life years and quality-adjusted life-years (QALYs) with higher reductions in hip and vertebral fracture incidence compared with patients with no pharmacologic treatment. The incremental cost-effectiveness ratio (ICER) was 119,575 Thai Baht (THB) per QALY for denosumab versus no pharmacologic treatment and 199,186 THB per QALY for denosumab versus alendronate. Among Thai postmenopausal women with high-risk of fractures, denosumab was cost-effective compared with no pharmacologic treatment at a willingness-to-pay threshold of 160,000 THB per QALY. One-way sensitivity analysis showed models were most sensitive to changes in denosumab pricing. Limitations: Data from other countries used when country-specific data were unavailable may not accurately reflect the true experience in Thailand. The model focused explicitly on hip, vertebral, and wrist fractures, and therefore provides a conservative estimate of the overall potential impact of osteoporosis-related fracture. The fracture risk was not adjusted to reflect potential changes in risk after denosumab treatment discontinuation. Conclusions: In Thailand, denosumab offers a cost-effective osteoporosis treatment option versus no pharmacologic treatment in postmenopausal women at high risk of fracture.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85080933599&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailanden_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1080/13696998.2020.1730381en_US
dc.identifier.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85080933599&origin=inwarden_US
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.